Currently the screening for lung cancer for risk groups is based on Computed Tomography (CT) or low dose CT (LDCT); however， the lung cancer death rate has not decreased significantly with people undergoing LDCT. We aimed to develop a simple reliable blood test for early detection of all types of lung cancer based on the immunogenicity of aberrant forms of BARD1 that are specifically upregulated in lung cancer.
Currently the screening for lung cancer for risk groups is based on Computed Tomography (CT) or low dose CT (LDCT); however， the lung cancer death rate has not decreased significantly with people undergoing LDCT. We aimed to develop a simple reliable blood test for early detection of all types of lung cancer based on the immunogenicity of aberrant forms of BARD1 that are specifically upregulated in lung cancer.
